PhaseLite™ is
clinically proven

2. PhaseLite™ significantly reduces the body weight of overweight and obese subjects

A 12-week randomised, double-blind, placebo-controlled bi-centric study comprising 123 overweight and obese subjects whose BMI
were between 25-35


"PhaseLite™ reduces body weight significantly in overweight and obese subjectsā€¯

Data on file, InQpharm Europe, 2012

Previous | Next

 
Copyright © 2015 by InQpharm Group. All rights reserved. Last updated: Oct 2015 | ID: MP/TM/EN/15/001
Phaselite and InQpharm are trademarks of the InQpharm group of companies.